NCT02097433View on ClinicalTrials.gov

Dacomitinib (PF-00299804) Pharmacokinetics In Chinese Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

14

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions

Healthy

Interventions

DRUG

Dacomitinib

A single 45 mg oral dose of Dacomitinib will be administered under fasted conditions to healthy Chinese volunteers

Trial Locations (1)

100032

Peking Union Medical College Hospital, Beijing

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Pfizer

INDUSTRY